-
First-in-class checkpoint inhibitor BI 765063 licensed to and being
developed under a collaboration agreement between Boehringer Ingelheim
and OSE Immunotherapeutics -
Clinical Trial Authorization and dosing of the first patient
triggers a total of €15 million milestone payments from Boehringer
Ingelheim to OSE Immunotherapeutics
INGELHEIM, Germany & NANTES, France–(BUSINESS WIRE)–Boehringer Ingelheim and OSE Immunotherapeutics SA (ISIN:
FR0012127173; Mnémo: OSE) today announce that the first patient has been
dosed in the first-in-human Phase 1 clinical trial evaluating BI 765063,
formerly OSE-172, a first-in-class monoclonal antibody antagonist of
SIRPα, being studied in patients with advanced solid tumors. The Phase 1
study is a dose finding study of BI 765063, a myeloid checkpoint
inhibitor, administered as a single agent and in combination with
Boehringer Ingelheim’s monoclonal antibody PD-1 antagonist BI 754091, a
T-lymphocyte checkpoint inhibitor.
“We are very pleased with the progress achieved on BI 765063’s program
and having the first patient dosed marks a significant milestone in the
product’s development. The advancement of a myeloid cell checkpoint
blocking monoclonal antibody into the clinic exemplifies Boehringer
Ingelheim’s commitment to the next wave of innovation in cancer
immunology therapies, with the goal of meaningfully improving outcomes
for patients with difficult-to-treat cancers” said Jonathon Sedgwick,
Ph.D., Senior Vice President and Global Head, Cancer Immunology & Immune
Modulation Research at Boehringer Ingelheim.
“We are excited to begin first-in-human testing with this novel
SIRPα-targeting compound, which we believe has first-in-class potential
in the treatment of solid tumors,” said Alexis Peyroles, chief executive
officer of OSE Immunotherapeutics. “This marks one of many anticipated
milestones in the collaboration agreement with our partner Boehringer
Ingelheim, and we look forward to advancing rapidly this potentially
transformative treatment through the clinic. Milestones such as this one
for the novel compounds our R&D teams develop have provided OSE with a
stable financial base to grow steadily our first-in-class
immuno-oncology pipeline.”
The study is conducted by OSE Immunotherapeutics as part of a
collaboration and license agreement under which Boehringer Ingelheim
obtained exclusive rights to BI 765063. Under the terms of the
collaboration and license agreement, the clinical trial authorization
obtained in March 2019 and dosing of the first patient in this Phase 1
trial triggers milestone payments of a total of €15 million to OSE
Immunotherapeutics from Boehringer Ingelheim. This trial aims to
characterize safety, pharmacokinetics, pharmacodynamics and preliminary
efficacy of the immunotherapy in patients with advanced solid tumours.
Please click on the link for “Notes to the Editors” and “References”
http://www.boehringer-ingelheim.com/press-release/bi-765064-sirp-antibody-phase-i-started
Contacts
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer
Ingelheim Corporate Center GmbH
Media + PR
press@boehringer-ingelheim.com
P:
+49 6132 77-90815
M: + 49 151 150 20 690
www.boehringer-ingelheim.com